The correlation of HPV16 and HPV18 with local vaginal immunity after the treatment of cervical intraepithelial neoplasia

被引:2
|
作者
Mu, Lin [1 ]
Miao, Jing-Rui [1 ]
Song, Jing-Hui [1 ]
机构
[1] Inner Mongolia Med Univ, Dept Obstet & Gynecol, Affiliated Hosp, 1 North Tongdao St, Inner Mongolia 100059, Peoples R China
基金
中国国家自然科学基金;
关键词
Cervical intraepithelial neoplasia (CIN); cervical squamous cell carcinoma; HPV; 16; 18; vaginal local immune factor; PROGRESSION; DNA;
D O I
10.21037/tcr-19-2955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study aimed to investigate the correlation between the level of HPV16 and HPV18 in patients with cervical lesions and the local vaginal immunity after receiving treatment with different degrees of cervical intraepithelial neoplasia (CIN) and cervical squamous cell carcinoma (CSCC). Methods: One hundred and thirty-six patients with LSIL (grade 1 CIN or CIN 1), 263 patients with HSIL (grade 2 and 3 CIN or CIN 2 and 3), and 33 patients with CSCC pathologically confirmed between November 2012 and September 2016 were assigned to the test group and 100 healthy women in the same period were assigned to the control group. ELISA was used to determine the levels of SIgA, IgG, IL-2, and IL-10 and the IL-2/IL-10 ratio in vaginal lavage fluid in the test group (before treatment and 3, 6, and 12 months after treatment) and the control group, respectively. Gene chip technology was adopted to test the HPV infection in the test group (before treatment and 3, 6, and 12 months after treatment) and the control group, respectively. Results: The results showed that the levels of SIgA, IgG, and IL-10 were positively correlated with the degree of cervical lesions and IL-2/IL-10 was negatively correlated with the degree in all patients before treatment. The levels of SIgA, IgG, and IL-10 were positively correlated with the degree of cervical lesions and IL-2/IL-10 was negatively correlated with the degree in HPV16 and HPV18-infected patients before receiving the treatment. Conclusions: The recovery after the treatment of HPV infection is time-dependent and the immune system of patients with CIN starts to recover in the 6th month after treatment, early intervention is not recommended. However, the immune system is approximately in a normal sate at 12 months after treatment, at which time the efficacy can be evaluated, and clinical intervention can be initiated if necessary. The level of local immune factors in the vagina can be monitored to determine the progression and prognosis of patients' cervical lesions.
引用
收藏
页码:4212 / 4223
页数:12
相关论文
共 50 条
  • [1] HPV16 and HPV18 genotyping in cervical cancer screening
    Ronco, Guglielmo
    Franceschi, Silvia
    Segnan, Nereo
    LANCET ONCOLOGY, 2011, 12 (09): : 831 - 832
  • [2] A comparison of methylation levels in HPV16, HPV18 and HPV51 genomes in asymptomatic HPV infection and cervical neoplasia
    Simanaviciene, V.
    Popendikyte, V.
    Gudleviciene, Z.
    Zilaitiene, B.
    Zvirbliene, A.
    HUMAN REPRODUCTION, 2015, 30 : 324 - 325
  • [3] Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
    Chua, Brandon Wen Bing
    Ma, Viva Yan
    Alcantar-Fernandez, Jonathan
    Wee, Hwee Lin
    INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2022, 67
  • [4] Different DNA methylation pattern of HPV16, HPV18 and HPV51 genomes in asymptomatic HPV infection as compared to cervical neoplasia
    Simanaviciene, Vaida
    Popendikyte, Violeta
    Gudleviciene, Zivile
    Zvirbliene, Aurelija
    VIROLOGY, 2015, 484 : 227 - 233
  • [5] Genetic diversity of HPV16 and HPV18 in Brazilian patients with invasive cervical cancer
    Vidal, Joao Paulo C. B.
    Felix, Shayany Pinto
    Chaves, Claudia B. P.
    Patury, Patricia
    Franco, Vanessa F.
    de Morais, Evaneide A.
    de Carvalho, Neile A.
    Carvalho, Aurenice C. L.
    Almeida Neto, Olimpio F.
    Vieira, Lina Maria T. M.
    Correa, Flavia Miranda
    Leite Martins, Luis Felipe
    Negrao, Antonio
    de Almeida, Liz Maria
    Martins Moreira, Miguel Angelo
    JOURNAL OF MEDICAL VIROLOGY, 2016, 88 (07) : 1279 - 1287
  • [6] Methylation of HPV18, HPV31, and HPV45 Genomes and Cervical Intraepithelial Neoplasia Grade 3
    Wentzensen, Nicolas
    Sun, Chang
    Ghosh, Arpita
    Kinney, Walter
    Mirabello, Lisa
    Wacholder, Sholom
    Shaber, Ruth
    LaMere, Brandon
    Clarke, Megan
    Lorincz, Attila T.
    Castle, Philip E.
    Schiffman, Mark
    Burk, Robert D.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (22): : 1738 - 1749
  • [7] HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels
    Fernandes, APM
    Gonçalves, MAG
    Duarte, G
    Cunha, FQ
    Simoes, RT
    Donadi, EA
    VIROLOGY, 2005, 334 (02) : 294 - 298
  • [8] Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16
    Ellis, JRM
    Etherington, I
    Galloway, D
    Luesley, D
    Young, LS
    LANCET, 1997, 349 (9058): : 1069 - 1070
  • [9] HPV-16 AND CERVICAL INTRAEPITHELIAL NEOPLASIA
    CROOK, T
    FARTHING, A
    VOUSDEN, K
    LANCET, 1992, 339 (8803): : 1231 - 1231
  • [10] Study of NK activity and detection of oncoviruses (HPV16, HPV18 and EBV) in cervical cancer in Tunisia
    Taamalli, H
    Rachdi, R
    Kochbati, L
    Slama, H
    Maalej, M
    Oueslati, R
    IMMUNOLOGY 2004: AUTOIMMUNITY, GENETIC AND DEGENERATIVE DISORDERS, MALIGNANCIES, AND TRANSPLANTATION, 2004, : 533 - 537